At Moderna Inc., our executive team plays a pivotal role in driving innovation and strategic growth in the biotechnology sector. Led by visionary leaders with diverse expertise and a commitment to advancing healthcare, our executives bring decades of combined experience to the forefront of mRNA technology.

Stéphane Bancel, Chief Executive Officer

Stéphane Bancel serves as the Chief Executive Officer of Moderna Inc., bringing over 20 years of experience in the biopharmaceutical industry. Under his leadership, Moderna has pioneered groundbreaking mRNA therapeutics and vaccines, revolutionizing the treatment landscape for infectious diseases and beyond.

Tal Zaks, Chief Medical Officer

Dr. Tal Zaks, as the Chief Medical Officer, leads Moderna's clinical development and regulatory affairs efforts. With a background in oncology and immunology, Dr. Zaks drives the clinical strategy behind Moderna's robust pipeline, ensuring rigorous scientific rigor and patient-centric innovation.

David Meline, Chief Financial Officer

David Meline serves as Moderna's Chief Financial Officer, overseeing financial operations and strategic planning. With extensive experience in finance and corporate strategy from his tenure at Amgen and 3M, Meline plays a crucial role in navigating Moderna through its rapid growth phase.

Stephen Hoge, President

As President of Moderna, Dr. Stephen Hoge oversees global commercialization and corporate affairs. His leadership is instrumental in expanding Moderna's global footprint and ensuring equitable access to transformative mRNA technology worldwide.

Lori Henderson, General Counsel

Lori Henderson serves as Moderna's General Counsel, responsible for legal and compliance matters. With a deep understanding of regulatory landscapes and corporate governance, Henderson ensures Moderna operates with the highest standards of ethics and integrity.

Marcello Damiani, Chief Digital and Operational Excellence Officer

Marcello Damiani leads Moderna's digital and operational strategies, driving efficiency and innovation across the organization. His expertise in digital transformation enhances Moderna's agility in responding to global health challenges and market demands.

Conclusion

In conclusion, Moderna Inc.'s executive team comprises industry leaders committed to advancing mRNA technology and transforming healthcare globally. Through their collective expertise and strategic vision, Moderna continues to pioneer new frontiers in biotechnology, delivering innovative solutions to improve patient outcomes worldwide.